
Dr. Damas DUKUNDANE
damas.dukundane@kfhkigali.com
+250 788 123 200
Profile
Dukundane Damas, MD, MMed, is a Medical Oncologist and Consultant Physician with more than ten years of experience in cancer care and internal medicine. He is licensed by the Rwanda Medical and Dental Council (Registration No. 1373) to practice both Internal Medicine and Medical Oncology. His clinical work focuses on the management of solid tumors—including breast, lung, gastrointestinal, and genitourinary cancers—along with early detection, prevention, and risk‑based screening. He is committed to patient education, advocacy, and shared decision‑making, and he integrates evidence‑based treatment, precision oncology, and supportive care into his practice.
Dr. Damas completed his medical degree at the National University of Rwanda (2010) and his Master of Medicine in Internal Medicine at the University of Rwanda (2016). He trained in Medical Oncology at Tata Memorial Hospital in Mumbai (2018) and later pursued advanced training in diagnostics and therapeutics for solid malignancies at Cliniques universitaires Saint‑Luc in Brussels (2025).
He has held several leadership roles, including serving as Head of Internal Medicine at King Faisal Hospital Rwanda (2020–2024) and President of the Rwanda College of Physicians (2022–2024). He currently leads the Oncology Unit at King Faisal Hospital, working closely with multidisciplinary teams to strengthen cancer services and improve patient pathways.
Dr. Damas is also a senior faculty member at the African Health Sciences University, where he teaches in the Department of Internal Medicine and contributes to curriculum development.
Alongside his clinical and academic responsibilities, he mentors trainees, participates in multidisciplinary tumor boards, and supports initiatives aimed at expanding access to quality oncology care in resource‑limited settings. His professional interests include research for quality improvement, patient‑centered cancer advocacy, and participation in clinical trials that broaden access to innovative therapies.

